Aptahem’s abstract for the ISICEM conference now published
Aptahem should have attended the ISICEM conference in Brussels these days, but it has been postponed until September 2020.
The abstract that the Aptahem team should have presented at the conference has however now been published in the Critical Care Magazine. The title is “A novel protein-binding RNA aptamer, Apta-1 – a new therapeutic tool to combat sepsis” and can be read below.
For further information:
Aptahem AB
Mikael Lindstam, CEO
Tel: +46 (0)766-33 36 99
Email: ml@aptahem.com
About Aptahem
Aptahem AB (APTA) is a biotechnology company that develops aptamer-based pharmaceuticals for the treatment of life-threatening conditions in which a combination of coagulation and inflammation are involved. The company’s primary pharmaceutical candidate, Apta-1, is being developed with the aim of preventing the high mortality rate caused by organ and tissue damage in sepsis patients, among others. The company possesses patent protection in strategic target markets and actively seeks business development opportunities with potential collaborators.